SCHEMBL19795212

SCHEMBL19795212

Cn1nc(N2CCCC2=O)c2ccc(N)cc21

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDB1 Q16531 4/20 0.65
CRBN Q96SW2 4/20 0.65
HSD17B10 Q99714 2/20 0.40
KMT2A Q03164 2/20 0.39
MAPK1 P28482 1/20 0.39
BRD9 Q9H8M2 1/20 0.39
MEN1 O00255 1/20 0.37
TSHR P16473 1/20 0.37
KDM4E B2RXH2 1/20 0.36
ALDH1A1 P00352 1/20 0.36
HPGD P15428 1/20 0.36
PIP4K2A P48426 1/20 0.36
PKM P14618 1/20 0.36
LMNA P02545 1/20 0.35
LRRK2 Q5S007 1/20 0.35
BRD4 O60885 1/20 0.34
BRDT Q58F21 1/20 0.34
ALOX5AP P20292 1/20 0.34
F10 P00742 1/20 0.34
BRPF1 P55201 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15081338 0.89 DDB1 (0.52) DDB1CRBNHSD17B10KMT2AMAPK1
SCHEMBL31520709 0.85 DDB1 (0.60) DDB1CRBNHSD17B10KMT2AMAPK1
SCHEMBL19795220 0.81 DDB1 (0.45) DDB1CRBNKMT2AMEN1KDM4E
SCHEMBL26621484 0.79 CRBN (1.00) DDB1CRBN
SCHEMBL25598339 0.77 DDB1 (0.56) DDB1CRBNHSD17B10KMT2AMAPK1
SCHEMBL16165270 0.74 L3MBTL1 (0.50) DDB1CRBNKMT2AMEN1KDM4E
SCHEMBL19795214 0.72 GRM4 (0.65)
SCHEMBL26637547 0.70 CRBN (0.55) DDB1CRBNBRPF1
SCHEMBL25175266 0.70 DDB1 (0.50) DDB1CRBNKDM4EALDH1A1BRPF1
SCHEMBL21000228 0.69 DDB1 (0.49) DDB1CRBNKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180022746-A1 INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2018-01-25 US disclosed
US-20180022746-A1 INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION VANDERBILT UNIVERSITY 2018-01-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180022746-A1 INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION GRIK4, GRM4, GRIA4 DDB1 2731/4885CRBN 2541/4885HSD17B10 3842/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.